USCOM LIMITED — Regulatory Filings 2014

Feb 23, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

Uscom BP+ new hypertension gold standard in children

Monday 24th of February 2014: Uscom (ASX code: UCM)

Uscom Limited is pleased to note the release of a new validation study comparing the Uscom BP+ measurements of central blood pressure (cBP) with the Sphygmocor (Atcor, Sydney, Australia) in children. The study concluded that the BP+ was at least as accurate as the reference gold standard, but was quick, and easy to use, well tolerated by children and suitable for clinical practice. The independent study was authored by world leading hypertension researchers from New Zealand.

The study compared results of cBP measurements using the Uscom BP+ suprasystolic oscillometry with the Sphygmocor radial artery applanation tonometer in 57 healthy children and found excellent agreement between cBP measures by both devices. The study stated that the tonometric techniques was user dependent, time consuming and challenging, especially when used on young children, and the use of a more simple method, BP+, would be a useful advancement. The BP+ measures the blood pressure close to the heart while the Sphygmocor measures the blood pressure in the wrist and estimates the central blood pressure.

This publication endorsing the BP+ in children follows last weeks publication of a review of cBP evidence in adults by Cambridge University and colleagues which found cBP was better than simple cuff BP measurements, and that the Uscom BP+ was the highest rated cBP device.

The current global BP and hypertension device market is estimated at approximately $2b USD and growing at 11.5% per year. The Uscom BP+ is a break through technology based on patent protected suprasystolic oscillometry and is changing worldwide thinking on hypertension. The Uscom BP+ has FDA clearance and has completed the CE Mark process to sell into Europe and is currently negotiating global distribution, sales and licensing deals to deliver the BP+ to market.

Executive Chairman of Uscom, Rob Phillips said, “This study further endorses the Uscom BP+ as the global leader in cBP technology. The BP+ provides accurate, simple and easy to operate access to cBP measurements and has now been endorsed as the preferred device and adults and children, and is planned for sale at approximately 20% of that of the competing product.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices changing the way we diagnose and treat circulatory disease, including hypertension and heart failure, and for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies.

References:

• Stoner L, Lambrick DM, Westrupp N, Young J, Faulkner J. Validation of Oscillometric Pulse Wave Analysis Measurements in Children. American Journal of Hypertension 2014, doi:10.1093/ajh/hpt243

• Lydakis C, Stefanaki E, Stefanaki S, Thalassinos E, Kavousanaki M, Lydaki D. Correlation of Blood Pressure, Obesity, and Adherence to the Mediterranean Diet with Indices of arterial Stiffness in Children. Eur J Pediatr (2012) 171:1373–1382 DOI 10.1007/s00431-012-1735-3

- McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/eurojeartj/eht565 (The Uscom BP+ is referred to as the Pulsecor Cardioscope II in the study)

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company (UCM). Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Bood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate & repeatable measurements of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in cardiology, intensive care, general practice and home care.

For more information, please visit: http://www.uscom.com.au

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au